Gout is the most common inflammatory arthritis and has effective treatments; it can
be cured by attaining serum urate targets with titration of urate-lowering therapy.
However, it remains unclear why treatment outcomes for people with gout are consistently
suboptimal. It seems reasonable to assume that the disruptions caused by the COVID-19
pandemic could have further worsened gout outcomes. In The Lancet Rheumatology, Mark
D Russell and colleagues1 have leveraged the digital infrastructure of the UK National
Health Service to report on gout care during the past 5 years in England, including
the COVID-19 pandemic.
be cured by attaining serum urate targets with titration of urate-lowering therapy.
However, it remains unclear why treatment outcomes for people with gout are consistently
suboptimal. It seems reasonable to assume that the disruptions caused by the COVID-19
pandemic could have further worsened gout outcomes. In The Lancet Rheumatology, Mark
D Russell and colleagues1 have leveraged the digital infrastructure of the UK National
Health Service to report on gout care during the past 5 years in England, including
the COVID-19 pandemic.
